Orange-yellow crystalline powder, odorless and tasteless. Melting point 196-198°C. Insoluble in water, slightly soluble in acetone, chloroform, benzene and ethanol.
Amoscanate (cgp4540) is phenyl isothiocyanate in which the hydrogen at the para-position has been replaced by a 4-nitroanilinyl group. Amoscanate is an anti-schistosomal agent. Amoscanate, as an isothiocyanate compound and uncoupler of oxidative phosphorylation, potently injures rodent ependyma[1].
ChEBI: Amoscanate is an isothiocyanate that is phenyl isothiocyanate in which the hydrogen at the para- position has been replaced by a 4-nitroanilinyl group. It has a role as a schistosomicide drug. It is a C-nitro compound, an isothiocyanate and a secondary amino compound. It is functionally related to a diphenylamine.
Mutation data reported. Ananthelmintic agent.
Amoscanate (500 mg/kg; p.o.; 10 days) destructs ependyma and periventricular brain[1].
Amoscanate (250 and 500 mg/kg; p.o.; 28 days) elicits necrosis, Ca++-positive microgranules, pyknosis and edema localized in ependyma/subependyma in the medial striatum[1].
Amoscanate (25~500 mg/kg; p.o.; 20 days) elicits progressive necrosis of ependyma[1].
Amoscanate elicits massive ultrastructural damage in ependymal cells[1].
| Animal Model: | Sprague-Dawley rats[1] |
| Dosage: | 500 mg/kg |
| Administration: | P.o.; 10 days |
| Result: | Destructed ependyma and periventricular brain.
|
| Animal Model: | Sprague-Dawley rats[1] |
| Dosage: | 250 and 500 mg/kg |
| Administration: | P.o.; 28 days |
| Result: | Elicited necrosis, Ca++-positive microgranules, pyknosis and edema localized in ependyma/subependyma in the medial striatum.
|
| Animal Model: | Sprague-Dawley rats[1] |
| Dosage: | 25~500 mg/kg |
| Administration: | P.o.; 20 days |
| Result: | Elicited progressive necrosis of ependymal.
|
[1] Johanson C, et al. The distributional nexus of choroid plexus to cerebrospinal fluid, ependyma and brain: toxicologic/pathologic phenomena, periventricular destabilization, and lesion spread. Toxicol Pathol. 2011;39(1):186-212. DOI:
10.1177/0192623310394214
